Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | FGFR2 K660N |
Therapy | Cediranib |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 K660N | Advanced Solid Tumor | sensitive | Cediranib | Preclinical - Cell culture | Actionable | In a preclinical study, Cediranib (AZD-2171) inhibited growth of transformed cells expressing FGFR2 K660N in culture (PMID: 23786770). | 23786770 |
PubMed Id | Reference Title | Details |
---|---|---|
(23786770) | Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. | Full reference... |